
Please try another search
Shanghai Bio-heart Biological Technology Co., Ltd. an interventional cardiovascular device company, engages in the research and development of therapies for unmet medical needs of patients in the People’s Republic of China. The company develops Bioheart, a bioresorbable scaffolds (BRS) system used in percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis 2nd, a renal denervation (RDN) product candidate for the treatment of uncontrolled hypertension and resistant hypertension; and drug coated balloon (DCB), a sirolimus drug-eluting balloon catheter designed for instent restenosis. Shanghai Bio-heart Biological Technology Co., Ltd. was founded in 2014 and is headquartered in Shanghai, the People’s Republic of China.
Name | Age | Since | Title |
---|---|---|---|
Li Wang | 56 | 2014 | Executive Chairman of the Board, CEO & GM |
Yunqing Wang | 39 | 2020 | CFO, Joint Company Secretary & Executive Director |
Peili Wang | 40 | 2018 | Financial Manager & Executive Director |
Xubo Lu | 43 | 2020 | Independent Non-Executive Director |
Lei Zhu | 38 | 2022 | Supervisor |
Yifei Jiang | - | 2024 | Independent Non-Executive Director |
Yiqing Chen | 40 | 2024 | Independent Non-Executive Director |
Tao Cai | 37 | 2020 | Chairperson of the Board of Supervisors & Head of Technology of BRS |
Junyi Wang | 34 | 2023 | Employee Representative Supervisor |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review